Teva takes issue with EC charges of pay-for-delay deal with Cephalon


At a hearing today , Teva Pharmaceutical Industries says it "responded robustly" to charges from the European Commission's competition watchdog that it entered into an illegal "pay-for-delay" deal with Cephalon to delay selling a generic version of its sleep disorder drug Provigil . The antitrust regulators claim that the deal may have inflated prices of the medication by up to 10%.



from Biotech News